RU
RUA.LSE Rua Life Sciences PLC
- Market cap
- GBX 17.9M
- P/E
- -
- P/B
- 2.53x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is RUA.LSE undervalued?
Graham numberThe Graham number of Rua Life Sciences PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rua Life Sciences PLC fundamental analysis
No fundamental analysis for Rua Life Sciences PLC yet.
Rua Life Sciences PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rua Life Sciences PLC
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and …
Full company profileRua Life Sciences PLC financial statements
Rua Life Sciences PLC annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 490K | 404K | 463K | 489K | 1.53M | 1.63M | 2.18M | 2.19M | 4.46M | 4.46M |
| Gross Profit | 266K | 404K | 463K | 489K | 980K | 1.05M | 1.43M | 1.72M | 3.06M | 3.06M |
| Operating Income | -199K | -289K | -632K | -991K | -1.80M | -2.35M | -2.31M | -1.94M | -827K | -827K |
| EBITDA | 42.2K | 185K | -391K | -703K | -1.28M | -2.04M | -1.95M | -1.57M | -383K | -383K |
| Net Income | -189K | -34.0K | -609K | -816K | -1.45M | -2.07M | -2.00M | -1.44M | -145K | -145K |
| EPS | -0.03 | -0.01 | -0.05 | -0.06 | -0.08 | -0.09 | -0.09 | -0.04 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 1.13M | 1.08M | 3.10M | 2.49M | 10.2M | 7.63M | 5.66M | 8.17M | 9.12M | - |
| Total Liabilities | 81.4K | 67.0K | 99.0K | 219K | 1.65M | 1.04M | 980K | 987K | 1.89M | - |
| Shareholders' Equity | 1.05M | 1.02M | 3.00M | 2.28M | 8.51M | 6.58M | 4.68M | 7.18M | 7.14M | - |
| Cash & Short-term Investments | 91.0K | 422K | 2.41M | 1.98M | 6.29M | 2.96M | 1.48M | 3.93M | 3.25M | - |
| Total Debt | - | - | - | - | 410K | 344K | 475K | 389K | 794K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -160K | 347K | -429K | -431K | -1.42M | -2.36M | -1.17M | -1.33M | -137K | - |
| Capital Expenditure | 1.00K | 16.6K | 1.00K | 5.00K | 620K | 904K | 449K | 55.0K | 161K | - |
| Free Cash Flow | -160K | 330K | -430K | -436K | -2.04M | -3.27M | -1.62M | -1.38M | -298K | - |
| Ratios | ||||||||||
| ROE | -18.0% | -3.3% | -20.3% | -35.9% | -17.1% | -31.4% | -42.8% | -20.1% | -2.0% | - |
| ROA | -16.7% | -3.1% | -19.7% | -32.7% | -14.3% | -27.1% | -35.4% | -17.6% | -1.6% | - |
| Net Profit Margin | -38.6% | -8.4% | -131.5% | -166.9% | -95.0% | -127.2% | -91.9% | -65.7% | -3.3% | -3.3% |
| Debt to Equity | - | - | - | - | 0.05x | 0.05x | 0.10x | 0.05x | 0.11x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rua Life Sciences PLC dividends
Rua Life Sciences PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Sep 1, 2003.
Who owns Rua Life Sciences PLC
- Insiders 19.16%
- Institutions 17.58%
- Public & others 63.26%
- Shares outstanding 62.1M
- Free float 50.4M
Rua Life Sciences PLC company profile
- Company name
- Rua Life Sciences PLC
- Ticker
- RUA.LSE
- ISIN
- GB0033360586
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 59
- Fiscal year end
- March
- Address
- 2 Drummond Crescent, Irvine, United Kingdom, KA11 5AN
- Phone
- 44 12 9431 7073
- Website
- rualifesciences.com
About Rua Life Sciences PLC
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric. It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Rua Life Sciences PLC management
2- Mr. William Donald BrownChief Executive Officer & Director · born 1963
- Mr. Lachlan Arthur SmithCFO, Company Secretary & Director · born 1980